Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

No benefit with adjuvant vitamin D in MS: meta-analysis

…in the SOLAR trial of interferon-β and adjunctive high-dose vitamin D (14,000 IU/day) (Hupperts et al. Neurology 2019;93:e1906-e1916). The proportion of patients achieving no evidence of disease activity (NEDA) at 48 weeks was 36.3% with vitamin D and 35.3% without vitamin D, although MRI outcomes (combined unique active lesions, T2 lesion volume) were improved with add-on therapy. A subsequent SOLAR subgroup analysis found that higher serum 25(OH…

McDonald criteria 2024: what changes can we expect?

…Hegen et al. Mult Scler 2023;29:182-195). One group has proposed kFLC analysis as the initial screening. An MS diagnosis could be made if the kFLC index >1; if <6.1, OCB testing would only then be performed (Monreal et al. Front Immunol 2023;14:1288169). The International Advisory Committee’s recommendations have not yet been made public so it is not known how the group will address these topics. Some details may be made available at the upcoming…

The year in review – 2023

…failed to meet its primary endpoint in its two EVOLUTION phase III trials (www.emdgroup.com/en/news/evobrutinib-phase-lll.html). The annualized relapse rate for evobrutinib in the two studies (0.11, 0.15) was similar to what was seen with teriflunomide (0.11, 0.14). Evobrutinib performed as expected: the unadjusted ARR was the same in the phase II trial (0.11 vs. 0.14 for DMF) (Montalban et al. N Engl J Med 2019;380:2406-2417) and the same (0.11)…

NfL a marker of microglial activation

…e lesions. Rim-active lesions are a particularly destructive aspect of the compartmentalized inflammation seen in progressive MS. Indeed, the authors noted that rim-active lesion volume accounted for >50% of the change in sNfL level. Thus, it appears that microglial activation both within the lesion and in the surrounding tissue is a major contributor to neuroaxonal damage. While sNfL is most strongly associated with focal inflammatory activity, t…

Biomarkers after stopping treatment may identify at-risk MS patients

…text at www.ncbi.nlm.nih.gov/pmc/articles/PMC10574823/pdf/NXI-2023-000383.pdf ). The study obtained serum NfL and GFAP levels before and after drug discontinuation in 78 MS patients. Patients were younger than those enrolled in recent discontinuation trials. Median age was 48.5 years, and median disease duration was 12.3 years. All participants had no clinical attacks or MRI activity for two years before and after drug discontinuation. Most patie…